Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 10 PH6 versus AMINOSYN 3 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 10 PH6 versus AMINOSYN 3 5 IN PLASTIC CONTAINER.
AMINOSYN 10% (PH6) vs AMINOSYN 3.5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Aminosin 3.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair and growth in patients unable to tolerate oral/enteral nutrition.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 mL/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Intravenous infusion of 500 mL to 1 L daily, providing 3.5% amino acids (31.5 g protein per liter). Administer at a rate not exceeding 100 mL/hour initially, adjusted based on metabolic tolerance.
None Documented
None Documented
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
The terminal elimination half-life of infused amino acids is approximately 18-24 minutes, reflecting rapid clearance from plasma into tissues for protein synthesis.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Amino acids are metabolized to urea and carbon dioxide; urea is excreted renally (90%) and to a lesser extent via sweat and feces (<10%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution